Literature DB >> 22575234

Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: a meta-analysis.

Xi Wu1, Ke-Fu Tang, Yang Li, Yu-Yu Xiong, Lu Shen, Zhi-Yun Wei, Ke-Jun Zhou, Jia-Min Niu, Xia Han, Lun Yang, Guo-Yin Feng, Lin He, Sheng-Ying Qin.   

Abstract

Leucine-rich repeat kinase 2 (LRRK2, PARK8) gene has attracted considerable attention since the variants in this gene are recognized as the most common cause of Parkinson's disease (PD) so far. A number of association studies concerning variants of LRRK2 gene and PD susceptibility have been conducted in various populations. However, some results were inconclusive. To derive a more precise estimation of the relationship between LRRK2 and genetic risk of PD, we performed a comprehensive meta-analysis which included 27,363 cases and 29,741 controls from 61 published case-control studies. Totally, the effect of five LRRK2 variants all within the coding regions, i.e. G2019S, G2385R, R1628P, P755L and A419V, were evaluated in the meta-analysis using fixed effect model or random effects model if heterogeneity existed. There were genetic associations between four variants (G2019S, G2385R, R1628P and A419V) and increased PD risk, while there was no evidence of statistically significant association between P755L and PD. Publication bias and heterogeneity were absent in most analyses. Within its limitations, this meta-analysis demonstrated that the G2019S, G2385R, R1628P and A419V variations are risk factors associated with increased PD susceptibility. However, these associations vary in different ethnicities.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575234     DOI: 10.1016/j.parkreldis.2012.04.013

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  15 in total

1.  Down-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity.

Authors:  Jerome A Roth; Michelle Eichhorn
Journal:  Neurotoxicology       Date:  2013-04-27       Impact factor: 4.294

2.  Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.

Authors:  Xiaodong Ding; Sandeep K Barodia; Lisha Ma; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2016-11-24       Impact factor: 5.996

Review 3.  Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease.

Authors:  Ravindran Kumaran; Mark R Cookson
Journal:  Hum Mol Genet       Date:  2015-06-22       Impact factor: 6.150

4.  Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.

Authors:  Julie Lake; Xylena Reed; Rebekah G Langston; Mike A Nalls; Ziv Gan-Or; Mark R Cookson; Andrew B Singleton; Cornelis Blauwendraat; Hampton L Leonard
Journal:  Mov Disord       Date:  2021-09-20       Impact factor: 9.698

Review 5.  Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.

Authors:  Dena G Hernandez; Xylena Reed; Andrew B Singleton
Journal:  J Neurochem       Date:  2016-04-18       Impact factor: 5.372

6.  Prevalence of Parkinson disease among the Navajo: a preliminary examination.

Authors:  Paul H Gordon; Hongwei Zhao; Denise Bartley; Lt James G Sims; Mae-Gilene Begay; Sarah Pirio Richardson; Johnnye Lewis; Andrew S Rowland
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

7.  Common variation in the LRRK2 gene is a risk factor for Parkinson's disease.

Authors:  Ignacio F Mata; Harvey Checkoway; Carolyn M Hutter; Ali Samii; John W Roberts; Hojoong M Kim; Pinky Agarwal; Victoria Alvarez; Renee Ribacoba; Pau Pastor; Oswaldo Lorenzo-Betancor; Jon Infante; María Sierra; Pilar Gómez-Garre; Pablo Mir; Beate Ritz; Shannon L Rhodes; Amy Colcher; Vivianna Van Deerlin; Kathryn A Chung; Joseph F Quinn; Dora Yearout; Erica Martinez; Federico M Farin; Jia Y Wan; Karen L Edwards; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2012-10-31       Impact factor: 10.338

8.  Genetic risk factors in Finnish patients with Parkinson's disease.

Authors:  Susanna Ylönen; Ari Siitonen; Michael A Nalls; Pauli Ylikotila; Jaana Autere; Johanna Eerola-Rautio; Raphael Gibbs; Mikko Hiltunen; Pentti J Tienari; Hilkka Soininen; Andrew B Singleton; Kari Majamaa
Journal:  Parkinsonism Relat Disord       Date:  2017-09-29       Impact factor: 4.891

9.  Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.

Authors:  Nicole Bryant; Nicole Malpeli; Julia Ziaee; Cornelis Blauwendraat; Zhiyong Liu; Andrew B West
Journal:  Hum Mol Genet       Date:  2021-04-30       Impact factor: 6.150

Review 10.  LRRK2: cause, risk, and mechanism.

Authors:  Coro Paisán-Ruiz; Patrick A Lewis; Andrew B Singleton
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.